Hyderabad to Witness ‘Global Voices, One Vision’ International Health Dialogue 2026, Hosted by Apollo Hospitals
The 13th edition of the International Health Dialogue (IHD) will be hosted by Apollo Hospitals in Hyderabad on January 30 and 31, 2026. The event will bring together global leaders to discuss patient safety, healthcare innovation, and system-wide transformation. The theme of IHD 2026, “Global Voices. One Vision,” emphasizes the shared commitment to building resilient, patient-centric, and technology-enabled healthcare systems. The two-day program will focus on leadership-driven safety models, human-centered design, digital transformation, and excellence in hospital operations, patient experience, and clinical outcomes.
The event will feature four major conferences: the International Patient Safety Conference, Healthcare Operations & Patient Experience Conference, Transforming Healthcare with IT Conference, and CLINOVATE, which will focus on the future of laboratories and diagnostics in patient safety and clinical decision-making. Global policymakers, including ministers of health from Niger, Papua New Guinea, and the Republic of Congo, will participate in the conference, along with prominent international experts such as Dr. Jonathan Perlin and Dr. Carsten Engel.
The conference will also include innovative features such as Safe-A-Thon, a collaborative challenge to develop practical patient safety solutions, and the launch of THNX, India’s first digital health startup community. THNX will facilitate pitch sessions, funding opportunities, and investor interactions. The event is expected to reinforce India’s growing role as a hub for global healthcare thought leadership and innovation.
According to Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals Group, the International Health Dialogue has evolved into a dynamic global platform where clinicians, innovators, and policymakers come together to shape the future of healthcare. The Hyderabad edition of IHD 2026 will bring together the power of AI, data, and digital ecosystems with the timeless values of empathy and collaboration to make healthcare more predictive, sustainable, and inclusive. With plenary sessions, innovation showcases, and global networking forums, the event is expected to be a significant gathering of global healthcare leaders.
Sun Pharma receives green light for obesity treatment injection similar to Wegovy.
Sun Pharmaceutical Industries has received approval for a weight loss injection similar to Novo Nordisk’s Wegovy. The new treatment, called “SUN-144”, is a once-weekly injection that helps with weight management in adults with obesity or overweight with at least one weight-related condition. This approval marks a significant milestone for Sun Pharma, as it enters the growing market for anti-obesity treatments.
Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been highly successful in treating obesity, with sales exceeding $1 billion in 2022. SUN-144 is also a GLP-1 receptor agonist, which works by mimicking a natural hormone that helps regulate appetite and food intake. Clinical trials have shown that SUN-144 is effective in reducing body weight and improving glycemic control in patients with type 2 diabetes.
The approval of SUN-144 is expected to increase competition in the anti-obesity market, which is currently dominated by Novo Nordisk’s Wegovy and Saxenda. However, Sun Pharma’s entry into the market may also lead to increased accessibility and affordability of these treatments, which could benefit patients who struggle with obesity and related health conditions.
Sun Pharma’s SUN-144 has shown promising results in clinical trials, with significant weight loss and improvements in cardiovascular risk factors. The treatment has also been well-tolerated, with common side effects including nausea, vomiting, and diarrhea. As the global prevalence of obesity continues to rise, the demand for effective and safe treatments is increasing. Sun Pharma’s entry into the market is expected to help meet this demand and provide patients with more options for managing their weight and related health conditions.
The approval of SUN-144 is a significant achievement for Sun Pharma, which has been expanding its portfolio of specialty and generic products. The company has a strong presence in the pharmaceutical industry, with a global footprint and a wide range of products. With the launch of SUN-144, Sun Pharma is poised to become a major player in the anti-obesity market, which is expected to continue growing in the coming years. As the company prepares to launch SUN-144, it is likely to focus on educating healthcare professionals and patients about the benefits and risks of the treatment, as well as its potential to improve health outcomes for individuals with obesity and related conditions.
Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.
Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest “A” leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin’s position among the world’s most sustainable and transparent companies. The double “A” rating reflects Lupin’s significant progress in mitigating climate risks, reducing carbon emissions, and ensuring responsible water management across its operations.
Compared to its previous ratings, Lupin has made substantial improvements, upgrading from “A-” in 2024 and “B” and “C” in 2023 for climate and water, respectively. This remarkable achievement demonstrates Lupin’s commitment to sustainability and its proactive initiatives to minimize its environmental impact. Ramesh Swaminathan, Executive Director and Global CFO, expressed pride in earning the double “A” rating, attributing it to the company’s innovative approaches, collaborative efforts, and transparent practices.
Lupin’s sustainability endeavors have also been recognized by S&P Global, which awarded the company an ESG score of 91 in 2025. This achievement places Lupin among an elite group of companies worldwide that have surpassed the 90-point threshold, demonstrating its best-in-class sustainability performance. The CDP’s strict framework has played a significant role in shaping and accelerating Lupin’s climate initiatives, driving ongoing progress and commitment to establishing new sustainability standards.
The recognition from CDP and S&P Global underscores Lupin’s dedication to generating lasting value for its communities and the planet. As a global pharma leader, Lupin is committed to reducing its environmental impact through innovation, collaboration, and transparency, setting a high standard for sustainability in the industry. With its exceptional achievements, Lupin continues to demonstrate its position as a responsible and sustainable business leader, driving positive change and promoting a more environmentally conscious future.
Zydus Lifesciences introduces India’s first biosimilar version of Nivolumab, a global breakthrough.
Zydus Lifesciences, a leading life sciences company, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha. This milestone marks a significant expansion of patient access to cutting-edge cancer therapies, particularly in the field of Immuno-Oncology. Tishtha will be available in two dosage strengths, 100 mg and 40 mg, priced at ₹28,950 and ₹13,950, respectively, which is approximately one-fourth of the reference product. This competitive pricing aims to improve treatment affordability and reduce the financial burden of cancer treatment.
The launch of Tishtha reinforces Zydus Lifesciences’ commitment to patient-centric care, with a focus on providing timely access to affordable and advanced cancer care. The company aims to support patients throughout their treatment journey, ensuring consistency, affordability, and reach. The development and manufacturing of Tishtha in India ensures long-term supply reliability, enabling patients to continue therapy without disruption.
The introduction of Tishtha in India significantly broadens access to advanced Immuno-Oncology treatments, making high-quality biosimilar immunotherapies accessible to a wider patient population. This launch is a pivotal step in Zydus Lifesciences’ efforts to make innovative, affordable healthcare solutions available to patients. By providing a reliable and consistent supply of Tishtha, the company aims to reduce clinical risk and financial stress associated with treatment interruptions.
According to Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences, every patient deserves timely access to affordable and advanced cancer care. The company’s commitment to patient access and affordability is reflected in the pricing of Tishtha, which is designed to minimize drug wastage and optimize dosing. With the launch of Tishtha, Zydus Lifesciences continues to play a leading role in advancing patient-centric Immuno-Oncology care in India, providing patients with access to innovative and affordable treatment options.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.